Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral ...
The combination drug elbasvir/grazoprevir (Zepatier, Merck) reduced viral load in patients with chronic hepatitis C virus (HCV) infection being treated for opioid addiction in a randomized controlled ...
Please provide your email address to receive an email when new articles are posted on . Measurements taken for HCV cure at 4 weeks produced identical results for people who inject drugs as those taken ...
As described in a recent JAMA Viewpoint, the proposed national HCV elimination program intends to engage underserved populations in need of HCV treatment by working closely with grassroots ...
The US Food and Drug Administration (FDA) on Tuesday released a revised version of its draft guidance on direct-acting antiviral (DAA) Hepatitis C virus (HCV) drugs, which calls on sponsors to conduct ...
The FDA is notifying health-care professionals about potential dangerous drug interactions between the hepatitis C virus (HCV) protease inhibitor boceprevir (Victrelis, Merck) and certain anti-HIV ...
Please provide your email address to receive an email when new articles are posted on . More frequent HCV testing was cost-effective among people who inject drugs in both high- and low-transmission ...
A new report questions the safety of some of the new drugs found to cure hepatitis C, in light of findings of liver failure and injury. But hepatitis C virus (HCV) experts say the findings are ...
Add Yahoo as a preferred source to see more of our stories on Google. Hepatitis C is an infection of the liver caused by the hepatitis C virus (HCV). Experts estimate that about 2.4 million people in ...
Prisoners bear much of the burden of the hepatitis C epidemic in the United States. Yet little is known about the scope and cost of treating hepatitis C in state prisons—particularly since the release ...
Additional Data Presented Demonstrate High In Vitro Antiviral Potency and In Vivo Efficacy for AT-587, Atea’s Potential First ...